Cargando…
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
BACKGROUND: A significant minority of asthma patients remain uncontrolled despite the use of inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA). A number of add-on therapies, including monoclonal antibodies (namely omalizumab) and more recently tiotropium bromide have been recommende...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789632/ https://www.ncbi.nlm.nih.gov/pubmed/29422778 http://dx.doi.org/10.1186/s12962-018-0089-8 |